Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase

Gene Therapy

Volumn 20, Issue 8, 2013, Pages 853-860

  Jonnalagadda, M ^a   Brown, C E ^a   Chang, W C ^a   Ostberg, J R ^a   Forman, S J ^a   Jensen, M C ^a,b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

DHFR; lentivirus; methotrexate; T cell selection

Indexed keywords

CD19 ANTIGEN; CD45RO ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; COMPLEMENTARY DNA; DIHYDROFOLATE REDUCTASE; EPIDERMAL GROWTH FACTOR RECEPTOR; L SELECTIN; LENTIVIRUS VECTOR; LEUCINE; LYMPHOCYTE ANTIGEN RECEPTOR; METHOTREXATE; PHENYLALANINE; RECOMBINANT DIHYDROFOLATE REDUCTASE MUTEIN; RECOMBINANT ENZYME; SERINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DNA MODIFICATION; GENE CONSTRUCT; GENE EXPRESSION; GENETIC SELECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS INACTIVATION; WILD TYPE;

ANTIGENS, CD19; CELL ENGINEERING; FOLIC ACID ANTAGONISTS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; LYMPHOCYTE ACTIVATION; METHOTREXATE; T-LYMPHOCYTES; TETRAHYDROFOLATE DEHYDROGENASE;

LENTIVIRUS;

EID: 84881478170     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.97     Document Type: Article

References (30)

1. Volpato JP, Mayotte N, Fossati E, Guerrero V, Sauvageau G, Pelletier JN. Selectively weakened binding of methotrexate by human dihydrofolate reductase allows rapid ex vivo selection of mammalian cells. J Mol Recognit 24: 188-198.
2. Milsom MD, Fairbairn LJ. Protection and selection for gene therapy in the hematopoietic system. J Gene Med 2004; 6: 133-146.
3. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIVinfected patients. Nat Med 1996; 2: 216-223.
4. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006; 107: 2294-2302.
5. Muul LM, Candotti F. Immune responses to gene-modified T cells. Curr Gene Ther 2007; 7: 361-368.
6. Milsom MD, Williams DA. Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection. DNA Repair 2007; 6: 1210-1221.
7. Fossati E, Volpato JP, Poulin L, Guerrero V, Dugas DA, Pelletier JN. 2-tier bacterial and in vitro selection of active and methotrexate-resistant variants of human dihydrofolate reductase. J Biomol Screen 2008; 13: 504-514.
8. Gatlin J, Douglas J, Evans JT, Collins RH, Wendel GD, Garcia JV. In vitro selection of lentivirus vector-transduced human CD34\+ cells. Hum Gene Ther 2000; 11: 1949-1957.
9. Allay JA, Persons DA, Galipeau J, Riberdy JM, Ashmun RA, Blakley RL et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med 1998; 4: 1136-1143.
10. Ragg S, Xu-Welliver M, Bailey J, D'Souza M, Cooper R, Chandra S et al. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res 2000; 60: 5187-5195.
11. Sorg UR, Kleff V, Fanaei S, Schumann A, Moellmann M, Opalka B et al. O6-methylguanine-DNA-methyltransferase (MGMT) gene therapy targeting haematopoietic stem cells: studies addressing safety issues. DNA Repair (Amst) 2007; 6: 1197-1209.
12. Larochelle A, Choi U, Shou Y, Naumann N, Loktionova NA, Clevenger JR et al. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. J Clin Invest 2009; 119: 1952-1963.
13. Sawai N, Zhou S, Vanin EF, Houghton P, Brent TP, Sorrentino BP. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther 2001; 3: 78-87.
14. Ercikan-Abali EA, Mineishi S, Tong Y, Nakahara S, Waltham MC, Banerjee D et al. Active site-directed double mutants of dihydrofolate reductase. Cancer Res 1996; 56: 4142-4145.
15. Lewis WS, Cody V, Galitsky N, Luft JR, Pangborn W, Chunduru SK et al. Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers. J Biol Chem 1995; 270: 5057-5064.
16. Flasshove M, Banerjee D, Bertino JR, Moore MA. Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant. Leukemia 1995; 9(Suppl 1): S34-S37.
17. Flasshove M, Banerjee D, Mineishi S, Li MX, Bertino JR, Moore MA. Ex vivo expansion and selection of human CD34\+ peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. Blood 1995; 85: 566-574.
18. Bertino JR. Cancer research: from folate antagonism to molecular targets. Best Pract Res Clin Haematol 2009; 22: 577-582.
19. Chunduru SK, Cody V, Luft JR, Pangborn W, Appleman JR, Blakley RL. Methotrexate-resistant variants of human dihydrofolate reductase. Effects of Phe31 substitutions. J Biol Chem 1994; 269: 9547-9555.
20. McIvor RS. Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application. Bone Marrow Transplant 1996; 18(Suppl 3): S50-S54.
21. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006; 66: 10995-11004.
22. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3: 35-45.
23. Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC. Engraftment of human central memory-derived effector CD8\+ T cells in immunodeficient mice. Blood 2011; 117: 1888-1898.
24. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008; 118: 294-305.
25. Crossland KD, Lee VK, Chen W, Riddell SR, Greenberg PD, Cheever MA. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol 1991; 146: 4414-4420.
26. Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996; 42: 1322-1329.
27. Zaharko DS, Fung WP, Yang KH. Relative biochemical aspects of low and high doses of methotrexate in mice. Cancer Res 1977; 37: 1602-1607.
28. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptidebased retroviral vector. Nat Biotechnol 2004; 22: 589-594.
29. Donnelly ML, Luke G, Mehrotra A, Li X, Hughes LE, Gani D et al. Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol 2001; 82: 1013-1025.
30. Stastny MJ, Brown CE, Ruel C, Jensen MC. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine\+ cytolytic T cells. J Pediatr Hematol Oncol 2007; 29: 669-677.